JOHN KIRKWOOD to Imidazoles
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Imidazoles.
Connection Strength
1.417
-
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
Score: 0.379
-
Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep; 9(9):496-7.
Score: 0.267
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov 07; 391(18):1709-1720.
Score: 0.152
-
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
Score: 0.116
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
Score: 0.105
-
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
Score: 0.102
-
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
Score: 0.091
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
Score: 0.067
-
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
Score: 0.055
-
Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
Score: 0.028
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.028
-
Reply to E. Hindi? and K.R. Hess. J Clin Oncol. 2019 05 20; 37(15):1356-1358.
Score: 0.026